 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Drugs that widen the airways of the lungs (bronchodilators) ease the breathing problems of patients with COPD. Drugs that decrease or prevent inflammation (corticosteroids) are also used, particularly in patients who have frequent bouts of worsening symptoms. However, whether the steroids really slow progression of COPD is not clear.
SUMMARIES FOR PATIENTS
Inhaled Steroids for Chronic Obstructive Lung Disease
17 June 2003 | Volume 138 Issue 12 | Page I-46
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Long-Term Effects of Inhaled Corticosteroids on FEV1 in Patients with Chronic Obstructive Pulmonary Disease. A Meta-Analysis." It is in the 17 June 2003 issue of Annals of Internal Medicine (volume 138, pages 969-973). The authors are K.B. Highland, C. Strange, and J.E. Heffner.
What is the problem and what is known about it so far?
Chronic obstructive lung (or pulmonary) disease (COPD) is a disease of the air sacs and air passages of the lungs. People with COPD are short of breath and sometimes cough and wheeze. Chronic obstructive lung disease is usually caused by smoking; damage to the lungs and symptoms slowly worsen over time. Most patients also have intermittent bouts of acute worsening of symptoms. Lung infections, cold weather, and exertion may cause these bouts.
Why did the researchers do this particular study?
To see whether inhaled corticosteroids slow the decline in lung function of patients with COPD.
Who was studied?
3571 adults with COPD who had participated in 6 different studies of long-term use of inhaled steroids.
How was the study done?
Rather than doing a new study, the researchers looked at previous randomized trials that had compared inhaled steroids with a placebo (dummy inhaler) in adults with COPD. All trials followed the lung function of participants for at least 2 years. Lung function was tested regularly with lung volume tests. The tests showed how much air remained in the lungs when breath was fully exhaled (forced expiratory volume or FEV1). Typically, FEV1 declines over time in patients with COPD. The researchers used a mathematical technique called meta-analysis to summarize the trials and see whether inhaled steroids reduced decreases in FEV1.
What did the researchers find?
The rate of FEV1 decline in patients given inhaled steroids and those given placebo did not differ significantly. Effects of steroids on symptoms and on numbers of bouts of worsening symptoms were inconclusive: Some trials showed benefits while others showed no benefits. Adverse effects of steroids were also inconclusive. One trial showed that long-term inhaled steroid use decreased the normal ability of the adrenal glands to produce steroid hormones, whereas another trial found no such effect. One trial found that long-term use of inhaled steroids decreased bone density, whereas another found no effects on bone.
What were the limitations of the study?
In four trials, one third to one half of the participants withdrew from the trials before the end of the minimum 24-month follow-up period.
What are the implications of the study?
Inhaled steroids probably don't affect long-term decline in lung function in patients with COPD. Tradeoffs between other potential clinical benefits and harms remain unclear.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. Suissa Lung function decline in COPD trials: bias from regression to the mean Eur. Respir. J., October 1, 2008; 32(4): 829 - 831. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Medications to Modify Lung Function Decline in Chronic Obstructive Pulmonary Disease: Some Hopeful Signs Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 322 - 323. [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli, N. E. Thomas, J. A. Anderson, G. T. Ferguson, C. R. Jenkins, P. W. Jones, J. Vestbo, K. Knobil, J. C. Yates, and P. M. A. Calverley Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa, P. Ernst, K. L. Vandemheen, and S. D. Aaron Methodological issues in therapeutic trials of COPD Eur. Respir. J., May 1, 2008; 31(5): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Fogarty, S. Jones, J. R Britton, S. A Lewis, and T. M McKeever Systemic inflammation and decline in lung function in a general population: a prospective study Thorax, June 1, 2007; 62(6): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Sutherland Inhaled Steroids and Outcomes in COPD: Progressing Beyond FEV1 Chest, March 1, 2007; 131(3): 648 - 649. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Soriano, D. D. Sin, X. Zhang, P. G. Camp, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, J. E. Connett, et al. A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo Chest, March 1, 2007; 131(3): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Niewoehner and T. J. Wilt Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease: A Status Report Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 103 - 104. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S. F. P. Man Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 1, 2006; 3(7): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J van der Palen, E Monninkhof, P van der Valk, S D Sullivan, and D L Veenstra Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease Thorax, January 1, 2006; 61(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D D Sin, L Wu, J A Anderson, N R Anthonisen, A S Buist, P S Burge, P M Calverley, J E Connett, B Lindmark, R A Pauwels, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease Thorax, December 1, 2005; 60(12): 992 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wilson, R. Adams, S. Appleton, R. Ruffin, and on behalf of the North West Adelaide (Cohort) Stud Difficulties Identifying and Targeting COPD and Population-Attributable Risk of Smoking for COPD: A Population Study Chest, October 1, 2005; 128(4): 2035 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes New approaches to COPD Eur. Respir. Rev., September 1, 2005; 14(94): 2 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Samet Inhaled Corticosteroids and Chronic Obstructive Pulmonary Disease: New and Improved Evidence? Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 407 - 408. [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C B Cooper and D P Tashkin Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease BMJ, March 19, 2005; 330(7492): 640 - 644. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Rennard Antiinflammatory Therapies Other Than Corticosteroids Proceedings of the ATS, November 1, 2004; 1(3): 282 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. El-Kassimi and N. A. Hanania Differentiating Asthma and COPD Patients Chest, August 1, 2004; 126(2): 653 - 655. [Full Text] [PDF]
|
|
|
|
|
|
D L Hahn, P S Burge, and S A Lewis Ethics of placebo controlled studies of inhaled steroids for COPD * Authors' reply Thorax, June 1, 2004; 59(6): 539 - 540. [Full Text] [PDF]
|
|
|
|
|
|
M G Duerden Do inhaled corticosteroids slow FEV1 decline in COPD after all? Thorax, June 1, 2004; 59(6): 538 - 539. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Greenstone Review: inhaled corticosteroids slow the progression of airflow limitation in COPD Evid. Based Med., May 1, 2004; 9(3): 75 - 75. [Full Text] [PDF]
|
|
|
|
|
|
P J. Rees Review: long acting {beta}2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease Evid. Based Med., May 1, 2004; 9(3): 79 - 79. [Full Text] [PDF]
|
|
|
|
|
|
S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones Impact of preventing exacerbations on deterioration of health status in COPD Eur. Respir. J., May 1, 2004; 23(5): 698 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction: Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Ann Intern Med, November 18, 2003; 139(10): 873 - 873. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Sutherland Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Ann Intern Med, November 18, 2003; 139(10): 864 - 864. [Full Text] [PDF]
|
|
|
|
|
|
P S Burge and S A Lewis So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all? Thorax, November 1, 2003; 58(11): 911 - 913. [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (25 Apr 2003 to 18 Jul 2003) Evid. Based Nurs., October 1, 2003; 6(4): e1 - 12. [Full Text]
|
|
|
|
|
|
P. E. Epstein Inhaled Corticosteroids and Chronic Obstructive Pulmonary Disease: Are We Barking Up the Wrong Tracheobronchial Tree? Ann Intern Med, June 17, 2003; 138(12): 1001 - 1002. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
